VIP
Vasoactive Intestinal Peptide
VIP is a 28–amino acid neuropeptide studied in research for vasodilatory, neuroendocrine, and immunomodulatory signaling.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
VIP is a 28–amino acid neuropeptide studied in research for vasodilatory, neuroendocrine, and immunomodulatory signaling.
Experimental models examine its receptor interactions (VPAC1/VPAC2) and downstream physiological pathways under controlled conditions.
Third-party tested for purity, ID, quantity.
Vasoactive intestinal peptide is a member of the secretin/glucagon peptide superfamily that signals through VPAC1 and VPAC2 receptors. Research has characterized its vasodilatory action, neuroendocrine roles, and immunomodulatory signaling across multiple systems.
Studies span cardiovascular, metabolic, and neuroimmune research frameworks under structured conditions.
VIP was isolated and characterized as a vasoactive peptide of intestinal origin, subsequently recognized as a broadly distributed neuropeptide.
Research has since examined its receptor biology and wide-ranging physiological roles.
Research into VIP focuses on VPAC-receptor signaling and neuroendocrine/immune regulation. Frameworks evaluate vasodilation, metabolic signaling, and neuroimmune endpoints under controlled conditions.
1 of the 4 areas below are addressed directly by a paper cited on this page.
VPAC1/VPAC2 receptor-signaling models
Addressed on this page by Hou 2022. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Hou, X. et al. (2022) — Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes
Vasodilation and cardiovascular research
No paper cited on this page reports on vasodilation or cardiovascular. This heading marks where VIP is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Neuroendocrine signaling studies
No paper cited on this page reports on neuroendocrine. This heading marks where VIP is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Neuroimmune-axis frameworks
No paper cited on this page reports on neuroimmune or axis. This heading marks where VIP is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 3 primary papers published between 1986 and 2022 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for VIP, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
VIP is also referred to as VIP peptide.
VIP is commonly described online in connection with weight loss, appetite suppression and fat reduction. In the research literature the same compound is filed under VPAC1/VPAC2 receptor-signaling models, vasodilation and cardiovascular research and neuroendocrine signaling studies.
The 3 papers cited on this page, published between 1986 and 2022 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of VIP is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy VIP in the United States through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
VIP is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 28 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (10mg / Single Vial, 10mg / 5-Pack, 10mg / 10-Pack available), batch-labelled
- Batch documentation for the lot shipped, once its certificate is published
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of vip. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Related
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
From$79.99
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$39.99
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$59.99
Long-acting amylin analog engineered for appetite signaling, metabolic control, and energy balance research
From$99.99